Antiproteinuric effect of renin-angiotensin system blockade in patients with normal/lower than 115 mmHg systolic blood pressure;Efecto antiproteinúrico del bloqueo del sistema renina-angiotensina (SRA) en pacientes con presión arterial sistólica inferior o igual a 115 mmHg

Nefrologia

Volumn 24, Issue 6, 2004, Pages 546-552

  Gutierrez E ^a   Gonzalez E ^a   Morales, E ^a   Herrero, J C ^a   Manzanera, M J ^a   Garcia J A ^a   Dominguez Gil B ^a   Hernandez E ^a   Praga, M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Blood pressure; Chronic renal insufficiency; Proteinuria; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 13844281403     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Praga M, Hernández E, Montoyo C, Andrés A, Ruilope LM: Long-term beneficial effects of ACE inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20: 240-248, 1992.
2. Praga M, Morales E: Renal damage associated with proteinuria. Kidney Int 62: S42-S46, 2002.
3. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M y cols.: Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 39: 1267-1273, 1991.
4. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: From ACEI to angioteinsin II antagonists. Kidney Int 57: 1803-1817, 2000.
5. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G: Proteinuria and blood pressure as casual components of progression to end-stage renal failure: Northern Italian Cooperative Study Group. Nephrol Dial Transplant 11: 461-467, 1996.
6. Praga M, Andrade CF, Luño J, Arias M, Poveda R y cols.: Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal disease: a double-blind, randomised clinical trial. Nephrol Dial Transplant 18: 1806-1813, 2003.
7. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 53: 1209-1216, 1998.
8. Brenner BM, Zagrobeiny J: Clinical renoprotection triais involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors. Kidney Int 63: S77-S85, 2003.
9. Deferrari G, Ravera M, Berruti V: Treatment of diabetic nephropathy in its early stages. Diabetes Metab Res Rev 19: 101-114, 2003.
10. Sato A, Tabata M, Hayashi K, Saruta T: Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensinconverting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. Clin Exp Nephrol 7: 215-220, 2003.
11. Shankland SJ, Johnson RJ: TGF-γ in glomerular disease. Miner Electrolyte Metab 24: 1 68-1 73, 1998.
12. Gunter W: Link between angiotensin II and TGF-β in the kidney. Miner Electrolyte Metab 24: 174-180, 1998.
13. Guijarro C, Egido J: Transcription factor-κβ (NF-κβ) and renal disease. Kidney Int 56: 118-134, 1999.
14. Lods N, Ferrari P, Fey FJ, Kappeler A, Berthier C y cols.: Angiotensinconverting enzyme inhibition but not angiotensin II receptor blockade regulates matriz metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 14: 2861-2872, 2003.
15. Rippe B: What is the role of albuminin proteinuric glomerulopathies? Nephrol Dial Transplant 19: 1-5, 2004.
16. Laverman GD, Henning RH, De Jong PE, Navis G, De Zeeuw D: Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 38: 1381-1384, 2001.
17. Kincaid-Smith P, Fairley K, Packham D: Randomized controlled crossover study the effect on proteinuria and blood pressure of adding and angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with renal disease and proteinuria. Nephrol Dial Transplant 17: 597-601, 2002.
18. Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C y cols.: ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomised, placebo-controlled study. Nephrol Dial Transplant 9: 265-269, 1994.
19. Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibition: A randomized and controlled trial. J Am Soc Nephrol 14: 1578-1583, 2003.
20. Lewis EJ, Hunsincker LG, Clarke WR, Berl T, Pohi MA y cols.: Renoprotective effect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
21. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE y cols.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
22. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S y cols.: The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
23. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G: Angiotensin converting enzyme inhibition ameliorates glomerular filtration and water and lessens glomerular injury in the rat. J Clin Invest 85, 541-549, 1990.
24. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkerneyer JA y cols.: Blocking angiotensin II syntesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 12: 941-948, 2001.
25. Cao Z, Bonnet F, Candido R, Nesteroff SP, Bums WC y cols.: Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 13: 1773-1787, 2002.
26. Patrakka J, Kestilä M, Wartiovaara J, Ruotsalainem V, Tissari P y cols.: Congenital nephrotic syndrome (NPHS1): Features resulting from different mutations in Finnish patients. Kidney Int 58: 972-980, 2000.